Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Catalyst Pharmaceuticals Inc CPRX

Healthcare Biotechnology

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for... see more

Add To Watchlist

Recent & Breaking News (NDAQ:CPRX)

Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra

GlobeNewswire January 23, 2023

Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®

GlobeNewswire January 23, 2023

Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd

GlobeNewswire December 19, 2022

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

GlobeNewswire November 9, 2022

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

GlobeNewswire November 7, 2022

Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

GlobeNewswire October 25, 2022

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients

GlobeNewswire September 29, 2022

Catalyst Pharmaceuticals Set to Join S&P SmallCap 600

PR Newswire September 12, 2022

Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 9, 2022

Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference

GlobeNewswire August 24, 2022

Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update

GlobeNewswire August 9, 2022

Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022

GlobeNewswire July 26, 2022

Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical

GlobeNewswire July 12, 2022

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

GlobeNewswire May 17, 2022

Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

GlobeNewswire May 10, 2022

Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

GlobeNewswire April 25, 2022

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

GlobeNewswire March 16, 2022

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

GlobeNewswire March 11, 2022

Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies

GlobeNewswire March 8, 2022

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022

GlobeNewswire March 3, 2022